文献速递骨软组织肉瘤与黑色素瘤

CT放射组学与临床模型预测晚期黑色素瘤检查点抑制剂治疗结局的比较

CT radiomics compared to a clinical model for predicting checkpoint inhibitor treatment outcomes in patients with advanced melanoma.
PubMed 文献 · Eur J Cancer · 2023-02-24

在9家医院回顾性纳入620例接受一线抗PD1±抗CTLA4治疗的晚期皮肤黑色素瘤患者,基于基线CT提取放射组学特征构建机器学习模型预测临床获益(稳定疾病超过6个月或RECIST 1.1缓解),其AUROC为0.607,低于临床模型的0.646,联合模型未改善判别或校准。

要点

  • 放射组学模型预测临床获益的AUROC为0.607(95%CI 0.562-0.652),低于临床模型的0.646(95%CI 0.600-0.692)。
  • 联合模型AUROC为0.636(95%CI 0.592-0.680),在判别和校准上均未优于临床模型。
  • 放射组学模型输出与临床模型5个输入变量中的3个显著相关(p<0.001)。

核心结论

  • 放射组学模型对临床获益具有中等预测价值且具统计学显著性,但未能为更简单的临床模型增加价值,可能因两模型学到的预测信息重叠。

研究设计与样本

  • 回顾性多中心队列研究,从9家参与医院识别接受一线抗PD1±抗CTLA4治疗的晚期皮肤黑色素瘤患者,共纳入620例。
  • 对每例患者在基线CT上分割最多5个代表性病灶并提取放射组学特征,训练机器学习流程预测临床获益(稳定疾病超过6个月或RECIST 1.1缓解)。
  • 采用留一中心交叉验证评估,并与基于既往发现的临床预测因素构建的模型比较,另构建放射组学与临床的联合模型。

主要发现

  • 620例中59.2%出现临床获益。
  • 放射组学模型AUROC为0.607(95%CI 0.562-0.652),低于临床模型的AUROC 0.646(95%CI 0.600-0.692)。
  • 联合模型在判别(AUROC 0.636,95%CI 0.592-0.680)或校准方面均未较临床模型改善。
  • 放射组学模型输出与临床模型5个输入变量中的3个显著相关(p<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Predicting checkpoint inhibitors treatment outcomes in melanoma is a relevant task, due to the unpredictable and potentially fatal toxicity and high costs for society. However, accurate biomarkers for treatment outcomes are lacking. Radiomics are a technique to quantitatively capture tumour characteristics on readily available computed tomography (CT) imaging. The purpose of this study was to investigate the added value of radiomics for predicting clinical benefit from checkpoint inhibitors in melanoma in a large, multicenter cohort. METHODS: Patients who received first-line anti-PD1±anti-CTLA4 treatment for advanced cutaneous melanoma were retrospectively identified from nine participating hospitals. For every patient, up to five representative lesions were segmented on baseline CT, and radiomics features were extracted. A machine learning pipeline was trained on the radiomics features to predict clinical benefit, defined as stable disease for more than 6 months or response per RECIST 1.1 criteria. This approach was evaluated using a leave-one-centre-out cross validation and compared to a model based on previously discovered clinical predictors. Lastly, a combination model was built on the radiomics and clinical model. RESULTS: A total of 620 patients were included, of which 59.2% experienced clinical benefit. The radiomics model achieved an area under the receiver operator characteristic curve (AUROC) of 0.607 [95% CI, 0.562-0.652], lower than that of the clinical model (AUROC=0.646 [95% CI, 0.600-0.692]). The combination model yielded no improvement over the clinical model in terms of discrimination (AUROC=0.636 [95% CI, 0.592-0.680]) or calibration. The output of the radiomics model was significantly correlated with three out of five input variables of the clinical model (p < 0.001). DISCUSSION: The radiomics model achieved a moderate predictive value of clinical benefit, which was statistically significant. However, a radiomics approach was unable to add value to a simpler clinical model, most likely due to the overlap in predictive information learned by both models. Future research should focus on the application of deep learning, spectral CT-derived radiomics, and a multimodal approach for accurately predicting benefit to checkpoint inhibitor treatment in advanced melanoma.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ter Maat LS, van Duin IAJ, Elias SG, et al. CT radiomics compared to a clinical model for predicting checkpoint inhibitor treatment outcomes in patients with advanced melanoma. Eur J Cancer. 2023. PMID: 36996627. doi:10.1016/j.ejca.2023.02.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。